Inhaled Corticosteroids Are Not Beneficial for Pulmonary Fibrosis
Inhaled corticosteroids should not be used for pulmonary fibrosis (IPF). The available evidence addresses only systemic corticosteroids, and even those are not recommended for stable IPF, with limited use reserved only for acute exacerbations 1.
The Evidence Against Corticosteroids in IPF
For Stable IPF: No Role for Any Corticosteroids
The pathophysiology of IPF fundamentally differs from inflammatory airway diseases where inhaled corticosteroids work. IPF is driven by epithelial injury and aberrant fibroproliferation, not by lymphocyte-mediated inflammation that corticosteroids target 2. The disease mechanism involves pro-fibrotic macrophages and myofibroblast activation—cell types that corticosteroids do not effectively modulate and may actually worsen through TGF-β pathway enhancement 2.
A 2023 systematic review found that corticosteroids had an uncertain effect on mortality (RR 1.03,95% CI 0.85-1.25) and an uncertain effect on FVC decline in IPF patients 3. Importantly, while corticosteroids might reduce FVC decline in non-IPF fibrotic lung diseases, they showed no benefit specifically in IPF (MD -3.80%, 95% CI -8.94% to 1.34%) 3.
Substantial Toxicity Without Proven Benefit
All patients in prospective studies experienced at least one steroid-related side effect 4. The risk-benefit ratio is unfavorable: corticosteroids carry substantial morbidity while their efficacy remains unproven after four decades of use 5, 4.
The Only Exception: Acute Exacerbations
For acute exacerbations of IPF only, systemic (not inhaled) corticosteroids may be considered, though the evidence is weak:
- The ATS/ERS/JRS/ALAT guidelines give a weak recommendation for systemic corticosteroids in acute exacerbations based on very low-quality evidence 1
- This recommendation is based solely on anecdotal reports and the high mortality of acute exacerbations, not on controlled trials
- Intravenous methylprednisolone (not inhaled) at doses up to 1 gram/day has been reported in case series 1
- Even in acute exacerbations, 90-day mortality remains 42% with corticosteroid treatment 6
Recent data suggest lower doses may be preferable: patients receiving 500-1000 mg/day (or 10 mg/kg/day) had lower 90-day mortality (39%) compared to those receiving 1000 mg/day (54%) 6.
Critical Pitfalls to Avoid
- Do not extrapolate from asthma or COPD: Inhaled corticosteroids work in inflammatory airway diseases but have no mechanistic rationale in fibrotic lung disease
- Do not use corticosteroids for stable IPF: The era of glucocorticoid therapy for stable IPF has ended—this represents a complete paradigm shift 2
- If treating acute exacerbation, use systemic not inhaled: The limited evidence that exists is for high-dose intravenous corticosteroids, not inhaled formulations 1
- Recognize that even "responders" may reflect disease heterogeneity rather than treatment effect: Better outcomes in some patients may indicate less severe disease, not corticosteroid efficacy 4
Current Standard of Care
Treatment for IPF has fully transitioned to antifibrotic therapy (nintedanib or pirfenidone), not corticosteroids 2. Supportive care remains the mainstay for acute exacerbations, with systemic corticosteroids as an adjunct of uncertain benefit 1.